Study: NCT06192160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg will be administered as one tablet orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: PZA will be administered as 500 mg tablets, based on weight, orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: EMB will be administered as 400 mg tablets, based on weight, orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: LZD 600 mg will be administered as one 600 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-223
Description: TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-223
Description: TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.